Published: Mar. 11, 2012
Updated: Mar. 11, 2012
Reporters & producers can visit Duke Medicine News and Communications for contact information.
By Duke Medicine News and Communications
A team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy tissue.
"Knowing the structure and properties of the transporter molecule may be the key to changing the way that some chemotherapies, for example, could work in the body to prevent tumor growth," said senior author Seok-Yong Lee, PhD, assistant professor of biochemistry at Duke.
The article was published in Nature online on March 11.
The transporter molecule, called a concentrative nucleoside transporter, works by moving nucleosides, the building blocks of DNA and RNA, from the outside to the inside of cells. It also transports nucleoside-like chemo drugs through cell membranes.
Once inside the cells, the nucleoside-like drugs are modified into nucleotides that are incorporated into DNA in ways that prevent tumor cells from dividing and functioning.
"We discovered the structure of the transporter molecule, and now we believe it is possible to improve nucleoside drugs to be better recognized by a particular form of the transporter molecule that resides in certain types of tissue," Lee said. "Now we know the transporter molecule has three forms, which recognize different drugs and reside in different tissues."
The team determined the chemical and physical principles a transporter molecule uses to recognize the nucleosides, "so if you can improve the interactions between the transporter and the drug, you won't need as much of the drug to get it into the tumor cells efficiently," Lee said. "Knowing the shape of the transporters will let scientists design drugs that are recognized well by this transporter."
Because the drugs enter healthy cells as well as tumor cells, giving a lower dose of drug that targets tumor tissue would be the best scenario, said Lee, who is also a member of the Duke Ion Channel Research Unit. "Healthy cells don't divide as often as tumor cells, so lowering the amount of drug given overall would be an effective approach to killing tumors while protecting patients."
The researchers studied transporter molecules from Vibrio cholera, a comma-shaped bacterium. The bacterial transporter serves as a good model system for studying human transporters because they share similar amino acid sequences. They found that both the human and bacterial transporter use a sodium gradient to import nucleosides and drugs into the cells.
The next step will be to try to understand which features of the transporter confer the ability to recognize certain chemo drugs and ultimately to design drugs that can easily enter the cells.
This work won a prize for Dr. Lee, the National Institute of General Medical Sciences Award, which he will receive at the Biophysical Society meeting in February.
The work was funded by the McKnight Endowment Fund for Neuroscience, the Alfred P. Sloan Foundation, the Klingenstein Fund, the Mallinckrodt Foundation, the Basil O'Connor Starter Scholar Research Award from the March of Dimes Foundation, and the NIH Director's New Innovator Award, in addition to start-up funds from the Duke University Medical Center.
Other authors include Zachary Lee Johnson and Cheom-Gil Cheong also of the Department of Biochemistry and the Ion Channel Research Unit.